NDP MP Gord Johns fêted as mental health champion - The Hill Times

Helen Branswell, 69, on Oct. 13 of cancer. Branswell, who originally hailed from Sherbrooke, Que., started freelancing for a small newspaper after graduating from St. Thomas University, which eventually led to a 30-year career with The Canadian Press (CP). Starting in 1986, Branswell first worked as a reporter-editor at CP’s Halifax bureau, then as a correspondent for CP in Calgary, covering local news, business, and sports, before going on to serve as a reporter and later editor with the Ottawa bureau from 1989 to 1995. She went on to do a five-year stint as a foreign correspondent, before returning to Toronto in 2000 and becoming focused on medical reporting during the SARS outbreak. She left CP in 2015 to join Boston-based STAT News, establishing herself as an expert with early insights into the COVID-19 pandemic. Branswell was frequently heard as an expert on CBC Radio, among other outlets. Among the accolades she received were the Victor Cohn Prize for Excellence in Medical Science Reporting and the George Polk Award for Public Service for her COVID reportage. She was also a Pulitzer Prize finalist and the recipient of an honorary degree from Carleton University.

Among cancer patients, the high financial cost of cancer care is a prevalent problem. This financial burden is also associated with potentially harmful behavioral strategies that patients might use to cope with costs, such as delaying or forgoing treatment and skipping medications. Collectively, researchers refer to this impact as financial toxicity.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.